What does optimal outreach, early detection, and preventive care for breast cancer look like? As a key member of two large research consortia focused on improving cancer screening and outcomes, Diana Buist is in a prime position to help answer this important question.
Dr. Buist is an epidemiologist and health services researcher whose work focuses primarily on early detection of breast cancer and reducing illness and death from breast cancer in populations. She is especially interested in translating research findings into clinically meaningful guidelines. Dr. Buist joined Group Health Research Institute (GHRI) in 1996 and within a few years became the Principal Investigator of the Group Health Breast Cancer Surveillance Project, one of seven sites participating in the National Cancer Institute's Breast Cancer Surveillance Consortium. She has also played a key role in several collaborative projects conducted by the HMO Cancer Research Network.
Her extensive experience working with these diverse data in longitudinal studies and randomized trials puts Dr. Buist in a unique position to examine cancer screening, care, and outcomes in health systems across the country. Because of her particular expertise in this area, she recently became a member of the Group Health-affiliated Evidence-based Practice Center—one of 11 centers funded by the Agency for Healthcare Research and Quality in 2012. Her role will include conducting systematic reviews for the U.S. Preventive Services Task Force.
Dr. Buist is an affiliate investigator at the Fred Hutchinson Cancer Research Center and an affiliate professor in the Departments of Epidemiology and Health Services at the University of Washington School of Public Health. She is also a senior scholar in residence at AcademyHealth. She enjoys sharing her expertise by mentoring junior faculty and PhD and MPH candidates, co-directing the CRN Scholars Program, and teaching courses in clinical outcomes research internationally through the American Thoracic Society.
Cancer screening and prevention; outreach and primary care prevention; comparative effectiveness; cost transparency; surveillance; secondary prevention; breast cancer treatment; breast cancer screening; outcomes following cancer diagnosis; cancer survivorship; provider variability in care
Cancer prevention and control; quality of care; preventive care; high-value care; consumer engagement in preventive medicine; systematic reviews
Cancer prevention and control
Drescher CW, Beatty JD, Resta R, Andersen MR, Watabayashi K, Thorpe J, Hawley S, Purkey H, Chubak J, Hanson N, Buist DS, Urban N. The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: results from a randomized controlled trial. Cancer. 2016 Jul 22. doi: 10.1002/cncr.30190. [Epub ahead of print]. PubMed
Elmore JG, Cook AJ, Bogart A, Carney PA, Geller BM, Taplin SH, Buist DS, Onega T, Lee CI, Miglioretti DL. Radiologists' interpretive skills in screening vs. diagnostic mammography: are they related? Clin Imaging. 2016 Jul 1;40(6):1096-1103. doi: 10.1016/j.clinimag.2016.06.014. [Epub ahead of print]. PubMed
Onega T, Weiss JE, Buist DS, Tosteson AN, Henderson LM, Kerlikowske K, Goodrich ME, O'Donoghue C, Wernli KJ, DeMartini WB, Virnig BA, Bennette CS, Hubbard RA. Breast MRI in the diagnostic and preoperative workup among Medicare beneficiaries with breast cancer. Med Care. 2016 Apr 22. [Epub ahead of print]. PubMed
Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DS, Anderson ML. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Apr 12. doi: 10.7326/M15-2117. [Epub ahead of print]. PubMed
Bowles EJ, Gao H, Brandzel S, Bradford SC, Buist DS. Comparative effectiveness of two outreach strategies for cervical cancer screening. Prev Med. 2016 Jan 25. pii: S0091-7435(16)00030-X. doi: 10.1016/j.ypmed.2016.01.016. [Epub ahead of print]. PubMed
Nichols HB, Bowles EJA, Islam J, Madziwa L, Sturmer T, Tran DT, Buist DS. Tamoxifen initiation after ductal carcinoma in situ. Oncologist. 2016 Jan 14. pii: theoncologist.2015-0310. [Epub ahead of print].
Dallal CM, Lacey JV Jr, Pfeiffer RM, Bauer DC, Falk RT, Buist DS, Cauley JA, Hue TF, LaCroix AZ, Tice JA, Veenstra TD, Xu X, Brinton LA. Estrogen metabolism and risk of postmenopausal endometrial and ovarian cancer: the B~FIT cohort. Horm Cancer. 2016 Jan. [Epub ahead of print]. PubMed
Buist DS, Chang E, Handley M, Pardee R, Gundersen G, Cheadle A, Reid RJ. Primary care clinicians' perspectives on reducing low-value care in an integrated delivery system. Perm J. 2015 Nov 2;20(1). doi: 10.7812/TPP/15-086. [Epub ahead of print]. PubMed
Chubak J, Bowles EJ, Yu O, Buist DS, Fujii M, Boudreau DM. Breast cancer recurrence in relation in antidepressant use. Cancer Causes Control. 2015 Oct 30. [Epub ahead of print].
Henderson LM, Weiss J, Hubbard RA, O'Donoghue C, DeMartini WB, Buist DS, Kerlikowske K, Goodrich M, Virnig B, Tosteson AN, Lehman CD, Onega T. Factors associated with preoperative magnetic resonance imaging use among medicare beneficiaries with nonmetastatic breast cancer. Breast J. 2015 Oct 28. doi: 10.1111/tbj.12522. [Epub ahead of print]. PubMed
Susan Brandzel, GHRI project manager, tells about two studies that are exploring personal experiences with a new cancer screening program.
Read it in Healthy Findings.
Dr. Eric B. Larson welcomes new GHRI leaders in research collaborations and translation.
Read it in Healthy Findings.
Sept. 28, 2015—CAD raises screening costs without benefit to patients and may miss cancers, large national BCSC study shows
Seattle Times, Sept. 28, 2015
Based on a new BCSC study, Dr. Diana Buist tells of technology that adds cost to breast cancer screening—without improving outcomes. Dr. Marc Mora comments.